Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II Study of Lenalidomide in Combination With Rituximab, Ifosfamide, Etoposide, and Carboplatin (RICER)

Next Previous
Trial Profile

Phase I/II Study of Lenalidomide in Combination With Rituximab, Ifosfamide, Etoposide, and Carboplatin (RICER)

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 18 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lenalidomide (Primary) ; Carboplatin; Carmustine; Cytarabine; Etoposide; Ifosfamide; Melphalan; Rituximab
  • Indications Diffuse large B cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms RICER

Most Recent Events

  • 22 Aug 2023 Status changed from active, no longer recruiting to completed.
  • 03 Feb 2014 Planned End Date changed from 1 Oct 2014 to 1 Dec 2014 ClinicalTrials.gov record.
  • 03 Feb 2014 Status changed from recruiting to active, no longer recruiting according to ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top